Do peri-operative high doses of intravenous glucocorticoids improve short-term functional outcome after direct anterior total hip arthroplasty? A randomized, single surgeon, placebo controlled, double blind study

开始日期2020-05-15

申办/合作机构

Katholieke Universiteit Leuven

CTIS2024-518452-23-00

/ Not yet recruiting临床3期IIT

A phase III, randomized, controlled, open label,no profit, single-center intervention study tocompare the effect of a conservative(antithyroid drugs) and an ablativeapproach (radioiodine or totalthyroidectomy) for the treatment ofhyperthyroidism in patients with Graves’disease and moderate-to-severe and activeGraves’ Orbitopathy (GO) treated withintravenous glucocorticoids (ABLAGO Study)

开始日期-

申办/合作机构

Azienda Ospedaliero-Universitaria di Modena

100 项与甲基安非他明相关的临床结果

登录后查看更多信息

100 项与甲基安非他明相关的转化医学

登录后查看更多信息

100 项与甲基安非他明相关的专利（医药）

登录后查看更多信息

11,831

项与甲基安非他明相关的文献（医药）

2025-10-01·TALANTA

Adhesive tapes as sampling probes and thermal desorption substrates, in search of direct analysis of particulate solid samples using Soft Ionization by Chemical Reaction In Transfer mass spectrometry

Article

作者: Calero-Cañuelo, Carlos ; Cárdenas, Soledad ; Lucena, Rafael

Direct analysis by mass spectrometry (MS) has emerged as a promising strategy for analyzing a broad range of samples. Among the different ionization techniques, plasma-based sources are simple alternatives that can be used to ionize a wide range of analytes, thus providing high analytical versatility. This article describes the design of a simple and cost-effective interface that uses adhesive tapes as both sampling probes and thermal desorption substrates. The particulate solid sample is adhered to the tape in a single and quick step, avoiding particle losses and protecting the interface from clogging. The probe is thermally desorbed in a dedicated chamber, built using commercial elements, in front of the MS inlet. The desorbed analytes are driven by the vacuum system (any supplementary carrier gas is not required), passing through the plasma-based source (Soft Ionization by Chemical Reaction In Transfer, SICRIT®), where they are ionized before being introduced in the spectrometer. The determination of caffeine in coffee has been evaluated as a proof of concept since the complexity of the matrix and the semivolatile character of the analyte can challenge the performance, allowing to check the potential of the new approach. The type of adhesive tape, the parameters related to the desorption and sample dilution have been studied in depth. Working under optimum conditions, LOD was settled down at 0.18 mg g^-1. The intra-day and inter-day precision, expressed as relative standard deviation and calculated at three different concentration levels, were better than 12.5 and 13.7 %, respectively. Finally, the accuracy of this method was calculated by analyzing five different coffee samples and comparing the results with those provided by a reference method. The accuracy was in the range of 82.3-105.5 %. This interface is presented as a promising, simple, solvent-free approach for the direct analysis of solid samples. The interface has been finally applied to the analysis of drug mixtures to demonstrate its versatility.

2025-10-01·TALANTA

Screening and validation of sponge materials assembled to a sampling device for enrichment and determination of amphetamine drugs in exhaled breath by HPLC-TQ-MS/MS

Article

作者: Yang, Xiangliang ; Xu, Fei ; Fan, Huajun ; Huang, Qingda ; Xu, Congfei ; Zhou, Jiedan ; Yang, Hai

Exhaled breath aerosol (EBA) analysis of the amphetamine drugs (AMPs) and ephedrine (EPH) has a great potential to monitor illicit drug abuse due to its simple, non-invasive, convenient, and easily accepted sampling. Nevertheless, the extremely low concentration of AMPs and EPH in EBA poses great challenges to instrumental analysis. In this study, a self-designed sampling device equipped with sponge-based material was developed and coupled to high-performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry (HPLC-TQ-MS/MS) for monitoring of the AMPs and EPH in EBA. Accordingly, the cellulose sponge with high adsorption performance and low expiratory resistance was screened out from multiple commercial sponges, optimized its configuration performance, and assembled to the sampling device, reaching the adsorption rates of 81.6 ± 2.2-98.9 ± 2.5 % for EPH and typical AMPs, including amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, and 3,4-methylenedioxymethamphetamine. The combination of HPLC-TQ-MS/MS and the device containing cellulose sponge showed excellent analytical performance, with linearity in the range of 30.0-20000.0 pg/filter (R ≥ 0.9901), low detection limit of 1.6-8.4 pg/filter, and the recoveries of 86.5-94.5 %. The device also exhibited good reusability and applicability for the simulated EBAs at different levels. Furthermore, the proposed method was successfully applied for determination of EPH in volunteers' EBAs, whose contents suggested a good correlation with that in saliva. Kinetic analysis provided insights into the adsorption mechanism, further validating reliability of the method. Overall, the simple, cheap, available, and reusable cellulose sponge assembled to sampling device was advantageous for enriching and monitoring of trace illicit drugs in human EBA.

2025-08-01·CHEMICO-BIOLOGICAL INTERACTIONS

Exposure of human neuroblastoma SH-SY5Y cells to amphetamine-type stimulants leads to oxidative-antioxidative imbalance associated with DNA damage and acetylcholine antagonism

Article

作者: Jurič, Andreja ; Zandona, Antonio ; Karačonji, Irena Brčić ; Canjuga, Irena ; Kozina, Goran ; Lovaković, Blanka Tariba ; Vrdoljak, Ana Lucić ; Kopjar, Nevenka ; Rešić, Arnes ; Pizent, Alica ; Katalinić, Maja ; Rašić, Dubravka ; Neuberg, Marijana

Amphetamine-type stimulants (ATSs) are widely abused substances that impair central and peripheral nervous system functions. The mechanisms of their toxicity on human neuronal cells have not been fully clarified yet but include effects on oxidative-antioxidative balance and interaction with synaptic enzymes/receptors. The aims of this study were to determine oxidant/antioxidant status, DNA integrity and the activity of neurotransmitter system components (monoamine oxidase A, MAO-A and nicotinic acetylcholine receptors, nAChR) in human neuroblastoma SH-SY5Y cells after 24-h exposure to different ATSs. In this matter, we first evaluated cell viability by MTS assay. After determination of the concentrations (near IC₂₅) suitable for conduction of the alkaline comet assay, these were further studied for the extent of DNA damage, along with the levels of malondialdehyde, reactive oxygen species (ROS), glutathione (GSH) and activities of antioxidative enzymes superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT). The activity of the MAO-A enzyme and nAChR activity were evaluated at concentration range 1-50 μM. Finally, the in silico pharmacokinetic parameters predictions of the tested ATSs were determined. When compared to untreated cells, the most notable result was obtained for amphetamine (AMP), where we observed a significant increase in ROS levels, SOD, GPx and CAT activity, and a decrease in GSH levels. Interestingly, all of the tested ATSs increased the activity of GPx, while the activities of the other enzymes were compound-dependent. The new psychoactive substance (NPS) mephedrone (4-MMC) had a similar effect as AMP, except that it did not affect CAT activity. At the tested concentrations, AMP, methamphetamine (METH) and 4-MMC also showed effects on DNA stability. None of the tested ATSs inhibited MAO-A in the tested concentration range, but AMP, METH, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) inhibited acetylcholine activation of human nAChR. Taken together, significant induction of oxidative stress parameters, increased level of DNA damage detected and inhibition of nAChR activity indicate potential mechanisms of ATS substances action, and represent the direction for further studies to clarify the toxicological risks associated with ATS and/or NPS consumption.

152

项与甲基安非他明相关的新闻（医药）

2025-07-15

·GlobeNewswire-Health Care

Intelligent Bio Solutions Adds Next-Gen Wearable for Extended Drug Detection to Product Offering, Strengthening Leadership in Non-Invasive Testing

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of the SmarTest® Patch to its portfolio of non-invasive drug testing solutions. The SmarTest Patch is an innovative wearable device, developed by SMARTOX®, that enables continuous drug detection through sweat over a 7 to 10-day period. The SmarTest Patch complements the Company's flagship product, the Intelligent Fingerprinting Drug Testing Solution, strengthening its product portfolio of sweat-based, non-invasive testing technologies. The SmarTest Patch is a discreet, water-resistant, and tamper-evident device worn on the skin for 7 to 10 days at a time, continuously collecting sweat to detect a broad range of substances, including cocaine, opiates, methamphetamines, marijuana and fentanyl, among others. The differing detection windows of the SmarTest Patch and the Intelligent Fingerprinting Drug Screening System allows INBS to address varied customer requirements across timeframes, while maintaining a consistent, non-invasive approach. The complementary products increase flexibility and choice for customers, strengthening the Company’s position as a leading provider of pain-free testing solutions. “The SmarTest Patch opens up new opportunities for us in markets where longer detection windows are critical, particularly in justice and rehabilitation settings,” said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. “It allows us to offer a more flexible and complete solution to our customers outside the U.S. and strengthens our position as demand continues to grow for non-invasive drug testing options.” The addition of the SmarTest Patch expands the Company's product offering and enhances its commercial edge, equipping customers with more adaptable tools to support short and long-term detection needs. About SMARTOX SMARTOX, founded in 2012, is a U.S.-based provider of drug and alcohol testing products and services. It offers a comprehensive portfolio supporting a wide range of settings, including healthcare, justice, corporate, and education. SMARTOX is committed to delivering advanced technology and exceptional results, providing fully integrated services encompassing design, customer service, and administrative support for its product line. The company's footprint spans the U.S. and international markets. SMARTOX is actively scaling its presence in forensic testing markets through new investments, pilot programs, and expanded jurisdictional coverage. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. For more information, visit http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company ContactIntelligent Bio Solutions Inc.  info@ibs.inc   LinkedIn | Twitter  Investor & Media ContactValter Pinto, Managing Director  KCSA Strategic Communications  PH: (212) 896-1254  INBS@kcsa.com

2025-02-27

·PRNewswire

CBSA launches Operation Blizzard to target fentanyl and other synthetic narcotics

OTTAWA, ON, Feb. 27, 2025 /PRNewswire/ - The Canada Border Services Agency (CBSA) plays an important role in keeping fentanyl, its precursors and other dangerous narcotics off our streets. Today, the CBSA shared details about additional actions being taken to stop fentanyl and other synthetic narcotics from reaching communities across the country and abroad. As part of Canada's Border Plan, the CBSA has launched Operation Blizzard, a targeted, cross-country initiative aimed at intercepting illegal contraband arriving and leaving Canada, with a focus on fentanyl and other synthetic narcotics. During this blitz, border services officers will be increasing examinations of inbound and outbound shipments. They will also be acting on increased referrals from CBSA's National Targeting Centre based on risk assessments. The goal of the operation is to disrupt the supply chain for fentanyl and other illicit drugs through interception of contraband as part of Canada's overarching efforts to strengthen border security and combat organized crime. In addition to Operation Blizzard, CBSA's collaborative efforts with the Royal Canadian Mounted Police and local law enforcement partners have resulted in significant seizures across the country. In February 2025 alone, the CBSA made six seizures amounting to 56.1g of fentanyl, including the seizure of 20 fentanyl pills and 23 g of a substance suspected to be fentanyl from two U.S. citizens crossing at the Windsor-Detroit Tunnel port of entry. The CBSA has also shared details about the following seizures of other illegal narcotics in the month of February: 186 kg of methamphetamine (estimated value of $1.86 million) and 42 kg of cocaine (estimated value of $1 million) at Coutts port of entry 6.4 kg of meth (estimated value of $500,000) in the Greater Toronto Area (GTA) 38 kg of cocaine (estimated value of $4.7 million) in the GTA 2.3 kg of cocaine (estimated value of $280,000) in the GTA 35 kg of ketamine (estimated value of $2.4 million) at Vancouver International Airport 30.6 g of suspected heroin (estimated value of $12,240) at the Peace Bridge port of entry 30 kg of suspected ketamine (estimated value of $2.1 million) in the GTA Quote "The Government of Canada is tackling the fentanyl crisis head on by disrupting the supply chain of fentanyl and its precursors. Operation Blizzard demonstrates our commitment to protecting North Americans and defending our borders from the organized crime groups who threaten our communities." - The Honourable David J. McGuinty, Minister of Public Safety "Canada is taking significant action to stop the importation, production and trafficking of illegal fentanyl. In addition to the deployment of new tools and technology at the border, we also rely heavily on our frontline personnel to secure our border. Exercises like Operation Blizzard deter criminals and help ensure that our border response to illegal drug trafficking is robust and effective." - Kevin Brosseau, Fentanyl Czar "The CBSA will not allow organized criminal organizations to exploit our borders. We are taking enhanced measures to prevent narcotics, synthetic opioids and fentanyl from reaching Canadians and from being exported to other countries. Operation Blizzard is one of the many steps we are taking to protect our communities from these dangerous substances." - Erin O'Gorman, President, Canada Border Services Agency Quick Facts Fentanyl is a very potent opioid pain reliever. A few grains can be enough to kill you. It is a dangerous drug that is 20 to 40 times more potent than heroin and 100 times more potent than morphine. This makes the risk of accidental overdose very high. In 2024, the CBSA made 28,325 illegal drug seizures, including 4.9 kilograms of fentanyl. For the latest statistics on CBSA's enforcement action seizures, visit Canada Border Services Agency seizures. On February 11, Prime Minister Justin Trudeau announced the appointment of Kevin Brosseau as Canada's Fentanyl Czar. Mr. Brosseau will work closely with U.S. counterparts and law enforcement agencies to accelerate Canada's ongoing work to detect, disrupt, and dismantle the fentanyl trade. The CBSA's response to the opioid crisis includes working with domestic and international law enforcement partners to identify and apprehend individuals, groups, and businesses that are suspected to be involved in the cross border movement of illicit drugs and substances. The CBSA also works with Health Canada in monitoring new and emerging threats of non-regulated substances that may be used for the illegal production of controlled substances, which can lead to scheduling of these chemicals under the Controlled Drugs and Substances Act. Canada's Border Plan is backed by an investment of $1.3 billion and built around five pillars: detecting and disrupting the fentanyl trade; new tools for law enforcement; enhancing operational coordination; increasing information sharing, and minimizing unnecessary border volumes. Contact the Border Watch Line to report suspicious cross-border activities using our secure web form or by calling 1-888-502-9060 toll-free. Follow us on X (@CanBorder), Instagram (@CanBorder), and join us on Facebook or visit our YouTube channel. SOURCE Canada Border Services Agency WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

2025-02-21

·drugs

OD Deaths Decline in U.S., Driven By Drop In Opioid Fatalities

FRIDAY, Feb. 21, 2025 -- America’s opioid crisis is showing signs of subsiding, a new report from the U.S. Centers for Disease Control and Prevention (CDC) says. Drug overdose deaths (OD) decreased by 4% between 2022 and 2023, according to the CDC’s National Center for Health Statistics. The overall OD death rate fell from 32.6 deaths per 100,000 people in 2022 to 31.3 deaths per 100,000 in 2023, the CDC says. This reduction was driven by a decline in OD deaths related to opioids, the report says. “Nationally, between 2022 and 2023, the age-adjusted rate of drug overdose deaths decreased for deaths involving any opioid and synthetic opioids other than methadone (which includes fentanyl ),” concluded the team led by senior researcher Arialdi Minino , a CDC statistician. However, OD deaths increased among users of stimulant drugs like methamphetamine and cocaine, researchers noted. Across the country, drug OD deaths decreased in 20 states and did not change significantly in 25 states, researchers found. The death rate increased in six states: Alabama, Alaska, California, Nevada, Oregon and Washington. Changes in OD death rates varied between states based on specific drug types, the report says: West Virginia (81.9 deaths per 100,000), the District of Columbia (60.7), Delaware (53), Tennessee (52.3), and Louisiana (50.6) had the highest OD death rates in the U.S. in 2023, researchers said. The states with the lowest rates were Nebraska (9 deaths per 100,000), South Dakota (11.2), Iowa (14.9), North Dakota (16.4), Montana (17.1), Arkansas (17.7), and Texas (18.5). Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 项与甲基安非他明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08187	甲基安非他明	N06BA03	DB01577

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑损伤	临床1期	美国	Sinapis Pharma, Inc.	-
脑损伤	临床1期	-	The University of Montana	-
脑损伤	临床1期	-	Sinapis Group	-
脑卒中	临床1期	美国	Sinapis Pharma, Inc.	-
脑卒中	临床1期	-	The University of Montana	-
脑卒中	临床1期	-	Sinapis Group	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MDS2017	N/A	-	-	Methamphetamine users (males)	製憲觸餘積夢憲獵範網(鹹顧鬱廠範願築鑰顧壓) = 膚鑰艱繭餘憲願範鏇獵積糧壓願餘衊構選鏇構 (憲蓋積網繭選窪簾壓繭 )	-	2017-06-04
				Methamphetamine users (females)	製憲觸餘積夢憲獵範網(鹹顧鬱廠範願築鑰顧壓) = 憲淵夢齋窪鹹蓋夢襯艱積糧壓願餘衊構選鏇構 (憲蓋積網繭選窪簾壓繭 )